Entrada Therapeutics Net Income Over Time
| TRDA Stock | USD 10.88 0.08 0.74% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Entrada Therapeutics Performance and Entrada Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Entrada Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.57) | Revenue Per Share | Quarterly Revenue Growth (0.92) | Return On Assets | Return On Equity |
Understanding Entrada Therapeutics requires distinguishing between market price and book value, where the latter reflects Entrada's accounting equity. The concept of intrinsic value - what Entrada Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Entrada Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Entrada Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Entrada Therapeutics and related stocks such as Humacyte, Achieve Life Sciences, and Voyager Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUMA | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (66.5 M) | (26.5 M) | (12 M) | (110.8 M) | (148.7 M) | (133.8 M) | (127.1 M) |
| ACHV | (8.9 M) | (14.7 M) | (21.1 M) | (31.8 M) | (26.2 M) | (16.8 M) | (20.1 M) | (10.6 M) | (12.7 M) | (16.1 M) | (14.7 M) | (32.9 M) | (41.9 M) | (29.8 M) | (39.8 M) | (35.8 M) | (34.1 M) |
| VYGR | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (16.3 M) | (29.7 M) | (40.2 M) | (70.7 M) | (88.3 M) | (40.8 M) | 36.7 M | (66 M) | (46.4 M) | 132.3 M | (65 M) | (74.8 M) | (71 M) |
| VNDA | (9.5 M) | (9.8 M) | (27.7 M) | (20.3 M) | 20.2 M | (39.9 M) | (18 M) | (15.6 M) | 25.2 M | 115.6 M | 23.3 M | 33.2 M | 6.3 M | 2.5 M | (18.9 M) | (220.5 M) | (209.5 M) |
| AVIR | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (13.5 M) | (10.9 M) | 121.2 M | (115.9 M) | (136 M) | (168.4 M) | (151.5 M) | (144 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.6 M) | (10.5 M) | (32.8 M) | (19.4 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | (29.7 M) | (80.9 M) | (72.8 M) | (69.2 M) |
| CAPR | (200) | (4.9 M) | (1.9 M) | (8.9 M) | (6.2 M) | (12.9 M) | (18.8 M) | 2.4 M | (15.2 M) | (7.6 M) | (13.7 M) | (20 M) | (29 M) | (22.3 M) | (40.5 M) | (36.4 M) | (34.6 M) |
| SGMT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (11.4 M) | (24.4 M) | (30.5 M) | (27.9 M) | (45.6 M) | (41 M) | (43.1 M) |
| IMRX | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (17 M) | (33.5 M) | (50.5 M) | (53.5 M) | (61 M) | (54.9 M) | (57.7 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (257.6 M) | (231.8 M) | (243.4 M) |
Entrada Therapeutics and related stocks such as Humacyte, Achieve Life Sciences, and Voyager Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Entrada Therapeutics financial statement analysis. It represents the amount of money remaining after all of Entrada Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Entrada Therapeutics | TRDA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | One Design Center |
| Exchange | NASDAQ Exchange |
USD 10.88
Check out Entrada Therapeutics Performance and Entrada Therapeutics Correlation. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Entrada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.